Evotec SE and Sandoz AG Plan Potential Sale of Just – Evotec Biologics Toulouse Site

SEC Filing 6-K (0001104659-25-071895)

Evotec SE and Sandoz AG have signed a non-binding agreement for the potential sale of the Just – Evotec Biologics EU site in Toulouse, France, for approximately US$ 300 million in cash. The deal includes additional technology-related considerations, future development revenues, milestones, and product royalties. Sandoz would assume full ownership of the site, while Evotec retains economic upside through revenue, milestones, and royalty optionality. The transaction aims to improve Evotec’s revenue mix, profit margins, and capital efficiency. The deal is subject to employee consultation, final agreements, and regulatory approvals. This move aligns with Evotec’s strategy to transition to an asset-lighter business model, leveraging its technology and IP for sustainable growth.